Sign in

CIK 0001789972

  • Non-accelerated filer
  • Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813879991
Phone
+1 617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Grant or award President and CEO acquired 180,000 shares (grant or award)
  2. 4 Grant or award Chief Medical Officer acquired 65,000 shares (grant or award)
  3. 4 Grant or award Chief Financial Officer acquired 60,000 shares (grant or award)
  4. 4 Planned sale Chief Scientific Officer sold 4,000 shares at $12.51 ($50,040)
  5. 4 Open-market sale President and CEO sold 8,400 shares at $11.87 ($99,708)
  6. 4 Open-market sale Chief Scientific Officer sold 4,693 shares at $11.41 ($53,547)
  7. 4 Open-market sale Chief Medical Officer sold 4,632 shares at $11.41 ($52,851)
  8. 4 Open-market sale Chief Legal Officer sold 3,482 shares at $11.41 ($39,730)
  9. 4 Open-market sale Chief Scientific Officer sold 3,489 shares at $12.52 ($43,682)
  10. 4 Planned sale Chief Scientific Officer sold 8,000 shares at $15.64 ($125,120)
  11. 4 Planned sale Chief Scientific Officer sold 8,000 shares at $18.09 ($144,720)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Derivatives Options or other derivatives
  14. 4 Planned sale Chief Scientific Officer sold 8,000 shares at $16.33 ($130,640)
  15. 4 Grant or award Chief Scientific Officer acquired 2,360 shares (grant or award)
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Option exercise Director acquired 18,450 shares (option exercise)

Page 4 of 13 · 253 filings